7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Osteitis D010000 10 associated lipids
Coronary Disease D003327 70 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Hip Fractures D006620 2 associated lipids
Osteolysis D010014 8 associated lipids
Hypothyroidism D007037 32 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Ha H et al. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. 2003 J. Biol. Chem. pmid:12637570
Ritchlin CT et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 2003 J. Clin. Invest. pmid:12639988
Takahashi E et al. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. 2002 J. Med. Dent. Sci. pmid:12641381
Fox SW et al. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. 2003 J. Immunol. pmid:12646633
Varsani H et al. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). 2003 Rheumatology (Oxford) pmid:12649407
Wise GE et al. Regulation of osteoprotegerin gene expression in dental follicle cells. 2003 J. Dent. Res. pmid:12651935
Schoppet M et al. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. 2003 Circulation pmid:12654623
Nakano M et al. Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. 2003 Oral Dis pmid:12657033
Ra JS et al. Osteoprotegerin inhibits proliferation of myeloid progenitor cells. 2003 J. Hematother. Stem Cell Res. pmid:12662434
Szalay F et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. 2003 J. Hepatol. pmid:12663228
Okada Y et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. 2003 J. Biol. Chem. pmid:12665515
Johnson-Pais TL et al. Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. 2003 Int. J. Cancer pmid:12673693
Zaidi M et al. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. 2003 J. Bone Miner. Res. pmid:12674320
Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. 2003 Blood pmid:12689925
Zheng B et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. 2003 Blood pmid:12689928
Moreno JL et al. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. 2003 Blood pmid:12689929
Dovio A et al. Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. 2003 J. Endocrinol. pmid:12697042
Bell NH RANK ligand and the regulation of skeletal remodeling. 2003 J. Clin. Invest. pmid:12697730
Eghbali-Fatourechi G et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. 2003 J. Clin. Invest. pmid:12697741
Enomoto H et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. 2003 J. Biol. Chem. pmid:12697767
Nakashima T et al. RANKL and RANK as novel therapeutic targets for arthritis. 2003 Curr Opin Rheumatol pmid:12707582
Al-Qawasmi RA et al. Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. 2003 J. Dent. Res. pmid:12709501
Fujita D et al. Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12711253
Tanaka S et al. Signal transduction pathways regulating osteoclast differentiation and function. 2003 J. Bone Miner. Metab. pmid:12720046
Valleala H et al. Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. 2003 Eur. J. Endocrinol. pmid:12720535
Yonou H et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. 2003 Cancer Res. pmid:12727825
Capparelli C et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. 2003 J. Bone Miner. Res. pmid:12733724
Wong T et al. Therapeutic implications for interferon-alpha in arthritis: a pilot study. 2003 J. Rheumatol. pmid:12734885
Lee ZH and Kim HH Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. 2003 Biochem. Biophys. Res. Commun. pmid:12745060
Boyle WJ et al. Osteoclast differentiation and activation. 2003 Nature pmid:12748652
Kanatani M et al. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. 2003 J. Cell. Physiol. pmid:12767054
Cheung J et al. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. 2003 J. Endocrinol. pmid:12773123
Nimmanapalli R and Bhalla K Targets in apoptosis signaling: promise of selective anticancer therapy. 2003 Methods Mol. Biol. pmid:12777745
Garber K Why it hurts: researchers seek mechanisms of cancer pain. 2003 J. Natl. Cancer Inst. pmid:12783923
Liu B et al. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. 2003 J. Oral Pathol. Med. pmid:12787044
Walsh MC and Choi Y Biology of the TRANCE axis. 2003 Jun-Aug Cytokine Growth Factor Rev. pmid:12787563
Eaton CL and Coleman RE Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. 2003 Cancer Treat. Rev. pmid:12787713
Fahrleitner-Pammer A et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. 2003 Wien. Klin. Wochenschr. pmid:12793029
Dovio A et al. Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. 2003 Clin. Cancer Res. pmid:12796409
Flick LM et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. 2003 J. Orthop. Res. pmid:12798068
Kido S et al. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. 2003 Bone pmid:12810169
Kudlacek S et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. 2003 Bone pmid:12810175
Khapli SM et al. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. 2003 J. Immunol. pmid:12816992
Kawase Y et al. Bone malformations in interleukin-18 transgenic mice. 2003 J. Bone Miner. Res. pmid:12817749
Kikuchi T et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. 2003 J. Dent. Res. pmid:12821717
D'Elia HF et al. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. 2003 Arthritis Res. Ther. pmid:12823855
Knudsen ST et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. 2003 Eur. J. Endocrinol. pmid:12824864
Ikeda T et al. Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. 2003 Pathol. Int. pmid:12828610
Crotti T et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. 2003 J. Periodont. Res. pmid:12828654
Tazoe M et al. Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. 2003 Arch. Oral Biol. pmid:12828991

Table of Content